FDA approves orphan-drug designation for Jaguar Health’s cholera drug, Crofelemer

Jaguar Health (NASDAQ:JAGX) family company Napo Pharmaceuticals announced on Tuesday that the U.S. Food and Drug Administration has granted orphan-drug designation to crofelemer, the company’s novel plant-based prescription drug, for treatment of diarrhea in cholera.
Crofelemer is also the subject

https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w750

2024-12-17 08:00:52